Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeit
about
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeit
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@en
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@nl
type
label
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@en
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@nl
prefLabel
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@en
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@nl
P2093
P356
P1433
P1476
Clinical and pharmacologic pha ...... (AIO) Phase I Group and Arbeit
@en
P2093
H H Fiebig
I M von Broen
R Velagapudi
W E Berdel
P304
P356
10.1023/A:1008430515881
P577
1998-12-01T00:00:00Z